Clinical data | |
---|---|
Pronunciation | /kloʊˈbeɪtəsɒl/[1] |
Trade names | Dermovate, Temovate, Clovate, others |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.042.380 |
Chemical and physical data | |
Formula | C25H32ClFO5 |
Molar mass | 466.97 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Clobetasol propionate is a corticosteroid used to treat skin conditions such as eczema, contact dermatitis, seborrheic dermatitis, steroid responsive dermatosis, and psoriasis (including scalp and plaque-type).[3][4][5]
It is applied to the skin as a cream, foam, gel, liquid, solution, ointment, or shampoo.[4][6][5] Use should be short term and only if other weaker corticosteroids are not effective.[6] Use is not recommended in rosacea or perioral dermatitis.[4]
Common side effects include skin irritation, dry skin, redness, pimples, and telangiectasia.[4] Serious side effects may include adrenal suppression, allergic reactions, cellulitis, and Cushing's syndrome.[4] Use in pregnancy and breastfeeding is of unclear safety.[7] Clobetasol is believed to work by activating steroid receptors.[4]
Clobetasol propionate was patented in 1968 and came into medical use in 1978.[8] It is available as a generic medication.[6] In 2022, it was the 156th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[9][10]